Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Beijing Tiantan Biological Products Corp Ltd

600161.SS ✓ COMPLIANTFree checks used up today ☆ Track — members

Shanghai Stock Exchange · Healthcare · Pharmaceuticals ·

China Mid Cap Analyst: BUY

Last Close

$1.85

▼ -0.49%

Market Cap $3.65B · Vol 10.71M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

34.77

FWD: 30.42

Market Cap

$3.65B

Mid Cap

Div Yield

1.22%

Semi-annual dividend

EPS Growth

-30.38%

YoY

RSI (14)

45.05

Momentum

Beta

0.46

vs Market

52W High

$2.81

29.65% below

52W Low

$1.67

12.91% above

Volume

10.71M

Avg 11.89M

P/B

2.73

Price-to-book

ROE

9.45%

Return on equity

Free Float

42.99%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Beijing Tiantan Biological Products Corp Ltd (600161.SS) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does 600161.SS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.57%

-2.22%

-4.05%

-13.67%

YTD

-24.66%

-32.84%

-43.76%

-38.60%

Financials & Valuation

TTM · Annual

Total Revenue	$882.02M
Net Income	$213.05M
Revenue Growth (YoY)	-16.56%
Gross Margin	43.54%
Operating Margin	29.32%
Net Profit Margin	24.15%
ROE	9.45%
ROA · ROIC	11.23% · 7.23%

P/E Ratio	34.77
Forward P/E (FY1)	30.42
PEG Ratio	-1.00
P/S	5.24
P/B	2.73
P/FCF	N/A
EPS Growth	-30.38%
Outstanding Shares	1.98B

Technical Indicators

50-Day SMA	$1.85
200-Day SMA	$2.09
RSI (14)	45.05
Beta	0.46
52-Week High	$2.81
52-Week Low	$1.67

Volume Today	10.71M
Avg Daily Volume (30D)	11.89M
Relative Volume	0.90x
Volatility (10D)	24.55
Volatility (30D)	24.74
Free Float	42.99%

Analyst Consensus

BUY

Current Price $1.85

Mean Target $2.13

52W Low$1.67 52W High$2.81

Current

Target

$1.67 $2.81

Current Analyst target

+15.20% upside potential · 2 analysts

Identifiers

ExchangeShanghai Stock Exchange

FIGIBBG001S6SRP6

ISINCNE000000WF9

CountryChina

Sub-IndustryBiopharmaceuticals

Earnings DateFeb 22, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. +13.33% CSL.AX CSL Limited +1.64% UCB.BR Ucb SA +0.50% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. +8.86% BIIB Biogen Inc. +1.59%

Company Profile

Beijing Tiantan Biological Products Corp Ltd is a China-based company principally engaged in the research and development, production and sales of blood products. The Company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human immunoglobulin, human rabies immunoglobulin, human hepatitis B immunoglobulin, human histamine immunoglobulin, human prothrombin complex and others. The Company's products are mainly used to treat shock caused by blood loss, trauma and burns, treat primary immunoglobulin G deficiency, neonatal sepsis, infant bronchiolitis, prevent and treat tetanus and others. The Company mainly operates its businesses in the domestic and overseas markets.